Drug intelligence / Profile preview

Lacrinorm

Development stage: Unknown
Lead developer: Farmigea
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

**Lacrinorm** is a Farmigea ophthalmic gel containing benzalkonium chloride and polyacrylic acid. It is used for disinfection of the ocular mucosa and as a lubricating, humectant treatment for tear insufficiency and dry eye syndrome. Benzalkonium chloride provides topical antiseptic activity, while the carbomer-based polyacrylic acid gel forms a lubricating, moisture-retaining coating over the ocular surface to relieve dryness and irritation.

Brand names: Lacrinorm

Beyond the preview

Go deeper on Lacrinorm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lacrinorm.

Explore the full profile